Clinical Trial Update: ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating erythropoietin alfa to prevent mortality and reduce severe disability in critically ill trauma patients, with recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Erythropoietin alfa (erythropoietin alfa)

Snippet

Sponsor: Australian and New Zealand Intensive Care Research Centre | Conditions: Trauma, Traumatic Injury | Phase 3 | Status: RECRUITING